Get all premium features to the best stock analysis tool

Adagio Medical Reports Fourth Quarter and Full Year 2025 Results

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the fourth quarter ended December 31, 2025. Fourth Quarter and Recent Business Highlights: Announced the peer-reviewed publication in Circulation: Arrythmia and Electrophysiology, highlighting results from the U.S. Early Feasibility Study evaluating ul.

Adagio Medical Announces Publication of Pre-Clinical Results for Next Generation Ventricular Ablation Catheter

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the publication of pre-clinical results of the Company's next generation ultra-low temperature ablation (“ULTA”) technology designed to treat ventricular arrhythmias. The publication, which is titled “Initial Pre‐Clinical Evaluation of the Augmented Ultra‐Low Temperature Cr.

Adagio Medical Highlights Recent Successful Expanded Access Cases with vCLAS™ System, Including Patients with Premature Ventricular Contractions (PVC)

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the successful completion of 13 ventricular ablation procedures at leading institutions using the Company's proprietary Ultra-Low Temperature Ablation (ULTA) technology under Expanded Access authorization from the U.S. Food and Drug Administration (FDA). The procedures addr.

Adagio Medical to Participate in the 38th Annual Roth Conference

LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) (“Adagio” or “the Company”), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be participating in the 38th Annual Roth Conference on March 23-24, 2026 in Laguna Niguel, CA and will be hosting one-on-one meetings with investors at the conference. For more information on the 38th Annual ROTH Conference, or to schedule a meeting wit.